ibb0979
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 28, 2023 (NCT05991583)
Timeline
Indications
Mechanism of action
- CD276 antigenINHIBITOR
inhibitor - CD276
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07076095 | Phase 2 | Aug 1, 2025 | SUNHO（China）BioPharmaceutical CO., Ltd., Zhengzhou University |
| NCT05991583 | Phase 1/Phase 2 (Phase 2) | Jun 28, 2023 | Huazhong University of Science and Technology, SUNHO（China）BioPharmaceutical CO., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SUNHO（China）BioPharmaceutical CO., Ltd. | For profit | 2 | 2 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1